Business Context and Reporting Period
This Form 8-K filing by PUMA BIOTECHNOLOGY, INC. (Delaware corporation) reports a corporate governance event dated January 19, 2012. The filing details the execution of a new Employment Agreement with Alan H. Auerbach, the Company's President and Chief Executive Officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
- Base Salary: $470,000 annually (retroactively effective September 1, 2011).
- Discretionary Bonus: Up to 50% of base salary.
- Equity Grant: Option to purchase 200,000 shares of common stock.
Material Changes
The primary material change is the formalization of Mr. Auerbach's employment terms, which govern his service since September 15, 2010. The agreement extends through September 1, 2014, with automatic one-year renewal terms unless terminated with 60 days' notice. The agreement also mandates that Mr. Auerbach be nominated for election to the Board of Directors if his directorship term expires during the agreement period.
Outlook, Risks, and Unusual Items
Severance Provisions:
- Change in Control: If terminated without "cause" or for "good reason" within 60 days prior to or 18 months following a change in control, Mr. Auerbach receives a lump sum equal to two times the sum of his base salary and maximum bonus, immediate vesting of all unvested equity awards, and up to 18 months of COBRA benefits.
- Standard Termination: If terminated without "cause" or for "good reason" outside the change in control context, he receives one year of salary and maximum bonus paid in installments, plus COBRA benefits.
Excise Tax: The Company agrees to pay or reimburse Mr. Auerbach for any excise tax imposed on payments made in connection with a change in control.
Restrictions: The agreement includes non-solicitation and non-disparagement provisions extending 18 months post-employment and indefinite confidentiality obligations.
Investor Verification Checklist
- Verify the vesting schedule for the 200,000 share option grant (1/3 on Jan 19, 2012; remainder monthly).
- Review the full text of Exhibit 10.1 for specific definitions of "cause" and "good reason."
- Confirm the impact of the retroactive salary adjustment on the Company's prior period financial statements.
- Assess the potential cash outflow liability under the change-in-control severance provisions.